Home Companies Catalysts Deep Dives
Keytruda pembrolizumab APPROVED
Drug Profile
ModalityAntibody
RouteIV
Therapy AreaOncology
Launch2014-09-04
US LOE2028-12-01
Peak Sales Est$30000M
Formulations[{"id":"keytruda-iv","doses":"200mg, 400mg","route":"IV","setting":"CLINIC","frequency":"Every 3-6 w
Companies
MRK (ORIGINATOR)100%
Mechanism: PD-1 inhibitor
Expert: Anti-PD-1 monoclonal antibody blocking immune checkpoint
Everyday: Helps immune system recognize and attack cancer
Targets: ["PD-1"]
Revenue History
PeriodRevenue ($M)
2023$25,011M
2024$29,482M
2025$31,700M
Q1 2024$6,947M
Q2 2024$7,270M
Q3 2024$7,429M
Q4 2024$7,836M
Q1 2025$7,210M
Q2 2025$7,650M
Q3 2025$8,100M
Q4 2025$8,740M
Programs (10)
IndicationStageKey StudyRegional Status
MelanomaAPPROVEDKEYNOTE-006[{"stage":"APPROVED","region":"US","approval_date":"2014-09-04"}]
NSCLC (1L)APPROVEDKEYNOTE-024/189[{"stage":"APPROVED","region":"US","approval_date":"2016-10-24"}]
HNSCCAPPROVEDKEYNOTE-048[{"stage":"APPROVED","region":"US","approval_date":"2019-06-10"}]
RCCAPPROVEDKEYNOTE-426[{"stage":"APPROVED","region":"US","approval_date":"2019-04-19"}]
Bladder (1L)APPROVEDKEYNOTE-361[{"stage":"APPROVED","region":"US","approval_date":"2017-05-18"}]
Gastric/GEJAPPROVEDKEYNOTE-859[{"stage":"APPROVED","region":"US","approval_date":"2023-12-01"}]
CervicalAPPROVEDKEYNOTE-826[{"stage":"APPROVED","region":"US","approval_date":"2021-10-13"}]
EndometrialAPPROVEDKEYNOTE-868[{"stage":"APPROVED","region":"US","approval_date":"2022-03-21"}]
TNBCAPPROVEDKEYNOTE-522[{"stage":"APPROVED","region":"US","approval_date":"2021-07-26"}]
HCCAPPROVEDKEYNOTE-394[{"stage":"APPROVED","region":"US","approval_date":"2023-10-31"}]
Upcoming Catalysts (2)
Sac-TMT + Keytruda - 1L NSCLC - Ph3 - Update (OptiTROP-Lung05) 2026
Keytruda - LOE Preparation Ongoing
Notes
Worlds best-selling drug. Approved in 40+ indications across 16+ tumor types. Key LOE risk in 2028.
Data from Supabase · Updated 2026-03-24